Axogen, Inc. Reports Third Quarter 2025 Financial Results

Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 millionALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third qua ...